Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer

Lee SH 1 , Menis J 2 , Kim TM 3 , Kim HR 4 , Zhou C 5 , Kurniawati SA 6 Show all authors , Prabhash K 7 , Hayashi H 8 , Lee DD 9 , Imasa MS 10 , Teh YL 11 , Yang JC 12 , Reungwetwattana T 13 , Sriuranpong V 14 , Wu CE 15 , Ang Y 16 , Sabando M 17 , Thiagarajan M 18 , Mizugaki H 19 , Noronha V 7 , Yulianti M 20 , Zhang L 21 , Smyth E 22 , Yoshino T 23 , Park JO 24 , Pentheroudakis G 25 , Park S 24 , Peters S 26 , Ahn JB 4 , Popat S 27

Affiliations 

  • 1 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. Electronic address: [email protected]
  • 2 Medical Oncology Department, University and Hospital Trust of Verona, Verona, Italy
  • 3 Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea
  • 4 Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
  • 5 Department of Medical Oncology, Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, China
  • 6 Department of Internal Medicine, Division of Hematology and Medical Oncology, Dharmais Cancer Hospital, National Cancer Center, Jakarta, Indonesia
  • 7 Department of Medical Oncology, Tata Memorial Center, Homi Bhabha National Institute, Mumbai, India
  • 8 Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan
  • 9 Department of Clinical Oncology, University of Malaya, Kuala Lumpur, Malaysia
  • 10 Department of Thoracic Oncology, Lung Center of the Philippines, Quezon City, Philippines
  • 11 Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
  • 12 Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan
  • 13 Division of Medical Oncology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
  • 14 Division of Medical Oncology, Faculty of Medicine, Chulalongkorn University and the King Chulalongkorn Memorial Hospital, Bangkok, Thailand
  • 15 Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan
  • 16 Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore
  • 17 Internal Medicine Department, Bicol Regional Hospital and Medical Center, Legazpi City, Albay, Philippines
  • 18 Department of Radiotherapy and Oncology, Kuala Lumpur Hospital, Kuala Lumpur, Malaysia
  • 19 Department of Respiratory Medicine, NHO Hokkaido Cancer Center, Sapporo, Japan
  • 20 Division of Respirology and Critical Care, Department of Internal Medicine, Faculty of Medicine Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • 21 State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China
  • 22 Department of Oncology, Oxford University Hospital NHS Foundation Trust, Oxford, UK
  • 23 Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
  • 24 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • 25 ESMO, Lugano, Switzerland
  • 26 Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland
  • 27 Royal Marsden NHS Trust, London, UK
ESMO Open, 2024 Nov 29;9(12):103996.
PMID: 39615406 DOI: 10.1016/j.esmoop.2024.103996

Abstract

The European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer (mNSCLC), published in January 2023, was modified according to previously established standard methodology, to produce the Pan-Asian adapted (PAGA) ESMO consensus guidelines for the management of Asian patients with oncogene-addicted mNSCLC. The adapted guidelines presented in this manuscript represent the consensus opinions reached by a panel of Asian experts in the treatment of patients with oncogene-addicted mNSCLC representing the oncological societies of China (CSCO), Indonesia (ISHMO), India (ISMPO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), the Philippines (PSMO), Singapore (SSO), Taiwan (TOS) and Thailand (TSCO), co-ordinated by ESMO and the Korean Society for Medical Oncology (KSMO). The voting was based on scientific evidence and was independent of the current treatment practices, drug access restrictions and reimbursement decisions in the different regions of Asia. The latter are discussed separately in the manuscript. The aim is to provide guidance for the optimisation and harmonisation of the management of patients with oncogene-addicted mNSCLC across the different regions of Asia, drawing on the evidence provided by both Western and Asian trials, while respecting the differences in screening practices, molecular profiling and age and stage at presentation. Attention is drawn to the disparity in the drug approvals and reimbursement strategies between the different regions of Asia.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications